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Abstract Placental fatty acid transfer in humans in vivo
was studied using stable isotopes. Four pregnant women un-
dergoing cesarean section received 4 h before delivery an









































1 h relative to time of
cesarean section. At the time of birth, venous cord blood
and placental tissue were collected. Fatty acid composition
was determined by gas-liquid chromatography and isotopic
enrichment by gas chromatography-combustion-isotope




C-enrichment of fatty acids in
the nonesterified fatty acids (NEFA) of cord plasma tended
to be higher than in NEFA of placenta, with statistically sig-


























































 0.003). The ra-
tio of tracer fatty acid concentrations of placenta to mater-






































These results suggest that only a part of the placental NEFA
participated in fatty acid transfer, and that the placenta
showed a preferential accretion of DHA relative to the
other fatty acids.—
 
Larqué, E., H. Demmelmair, B. Berger,
U. Hasbargen, and B. Koletzko.
 
 In vivo investigation of the




































The rapid growth and development of the fetus depends
on a sufficient supply of nutrients across the placenta. An ade-
quate supply of long chain polyunsaturated fatty acids
(LC-PUFA), such as arachidonic acid (C20:4n-6, AA) and
docosahexaenoic acid (C22:6n-3, DHA), is critical for the
early development of the brain and visual function (1, 2).
 
Numerous studies have reported that, in contrast to essential
fatty acids (EFA), LC-PUFA percentages in the lipids of cord
plasma are higher than in maternal plasma at the time of
birth (3, 4). Since the ability of the fetus and the human pla-
centa to desaturate and elongate fatty acids is limited (5), a
preferential materno-fetal transfer of LCPUFA has been sug-
gested. However, the underlying processes for placental fatty
acid transfer have not been elucidated.
Fatty acids are released from maternal triglycerides (TG)
by lipoprotein lipase on the maternal surface of the placenta
(6–8) and the liberated fatty acids, as well as nonesterified
fatty acids (NEFA) from the circulation, can be utilized by
the placenta. The placental transfer of fatty acids is con-
sidered a complex process that involves their binding to
membrane proteins and cytoplasmatic transport proteins
(8). Fatty acids may be esterified in the placenta and cross
the tissue in either direction (8). Recently, in vitro studies
have identified a placental plasma membrane fatty acid
binding protein (p-FABPpm), which showed a higher af-
finity and binding capacity for DHA and AA compared
with linoleic acid (LA, C18:2n-6) and oleic acid (OA,
C18:1n-9) (9). Thus, p-FABPpm facilitates the observed
preferential transfer of LC-PUFA. Kuhn and Crawford
(10) reported that LA and AA were passed to the developing
fetus in different lipid fractions during placental perfusion
experiments, suggesting that a compartmentalization of fatty
acids by the placenta might contribute to the selective
transfer of some fatty acids.
In placental perfusion studies, nonesterified LA and
palmitic acid (PA, C16:0) cross the placenta at similar
rates (11, 12), and LA shows a relative preference for the
transfer from the maternal to the fetal circulation com-
pared with AA (10). From human placental perfusion
studies, transfer selectivity of the placenta from the mater-
 
Abbreviations: AA, arachidonic acid, C20:4n-6; APE, atom percent
excess; DHA, docosahexaenoic acid, C22:6n-3; LA, linoleic acid,
C18:2n-6; LC-PUFA, long-chain polyunsaturated fatty acids; NEFA,
nonesterified fatty acids; PA, palmitic acid C16:0; PL, phospholipids;
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nal to the fetal circulation has been reported to decrease




-linolenic acid (ALA) to LA, to OA, and to
AA (13). However, substrates may be metabolized within
the placenta itself and the fatty acid release from albumin
limits the rate of transfer of fatty acids across the tissue
(14). Therefore, data derived from perfusion experiments
may not reflect in vivo transfer of fatty acids.
Fatty acids labeled with stable isotopes are safe and can
be used in pregnant women (15), allowing the study of
human placental transport under in vivo conditions. Since
the distribution of individual fatty acids in plasma and pla-
centa might influence their selective materno-fetal trans-

















C]DHA given orally to














 SD) of gestation in the Dept. of Gynecol-
 
ogy and Obstetrics (University of Munich, Grosshadern, Germany)
participated in the study. The study protocol was approved by the
Ethical Committee of the Ludwig-Maximilians University. Written in-
formed consent was obtained from all participating women after














 11 cm. All subjects habitually consumed an omnivorous diet
and none reported any health problems or pregnancy complications.
Four hours before delivery, the subjects received one oral dose




C-labeled fatty acids (Martek, Bioscience,


















The tracers were supplied as free fatty acids on a sugar cube to
the pregnant women, who were fasted for at least 12 h and did
not eat during the study period.
 
Blood and placenta sampling
 






















1 h. Blood samples (3 ml) were taken by venipuncture
and immediately transferred into EDTA-containing tubes.
Venous cord blood was sampled immediately after clamping the
cord. Blood cells and plasma were separated within 1 h by cen-
















C for later analysis.
 




 SE) of maternal plasma, venous cord plasma and placental 
tissue at the time of birth
 
































































































































































































































0.18  0.02a 
Cholesterol esters
PA 13.54  0.68 22.04  1.24b 20.28  0.54
OA 19.85  0.75 24.33  1.55b 16.61  0.87
LA 46.61  2.37 18.35  0.69b 27.05  1.99
DHA 0.80  0.12 1.18  0.20 1.86  0.13
Total PUFA 57.43  1.81 37.25  0.68b 44.88  0.72
Total LC-PUFA 9.44  1.03 18.09  0.47b 16.67  1.29
Total FA (mg/dl) 75.67  9.15 19.20  3.03 0.11  0.01a
Nonesterified fatty acids
PA 31.28  0.75 27.59  1.15 25.02  1.28
OA 27.59  2.21 13.22  1.13b 9.56  0.61
LA 10.08  0.42 9.79  0.06 8.71  0.37
DHA 1.03  0.32 4.19  0.29 4.86  0.47
Total PUFA 15.56  1.48 35.09  0.45 44.79  1.42
Total LC-PUFA 4.72  1.55 24.88  0.40b 35.63  1.30
Total FA (mg/dl) 25.86  11.36 6.52  2.00b 0.54  0.20a 
 PA, palmitic acid (C16:0); OA, oleic acid (C18:1n-9); LA, linoleic acid (C18:2n-6); DHA, docosahexaenoic
acid (C22:6n-3); PUFA, polyunsaturated fatty acids; LC-PUFA, long-chain polyunsaturated fatty acids ( 20 C at-
oms,  two double bounds); FA, fatty acids. FA proportions of the placenta were not considered in the statistical
analysis because they are data from a tissue and not plasma.
a In placenta, total FA is expressed in mg/g wet weight.
b Significant differences between FA proportions in maternal and cord plasma (P 	 0.05).
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The total placenta was weighed immediately after delivery.
Samples of 1 
 1 
 1 cm of placenta cotyledons were cut with a
sharp knife. Placenta samples were subjected to three washings
with a 0.9% NaCl solution until blood was eliminated as far as
possible, frozen in liquid nitrogen, and stored at 80C until
later analysis.
Analysis of plasma and placenta fatty acids
After addition of internal standard, total lipids from 0.1 ml of
plasma were extracted into hexane-isopropanol (4:1, v/v) (16).
Lipids from placenta tissue were extracted into chloroform-
methanol (2:1, v/v) (17). For application on silica gel plates
(MERCK, Darmstadt, Germany), the residue was taken up in
chloroform-methanol (1:1, v/v). Phospholipids (PL), TG, cho-
lesterol esters (CE), and NEFA were isolated by development of
the plates in n-heptane-diisopropylether-glacial acetic acid
(60:40:3, v/v/v) (18). Synthesis of fatty acid methyl esters was
performed with 3M methanolic HCl (Supelco, Bellafonte, PA) at
85C for 45 min. Derivatives were extracted into hexane and
stored at 20C until gas chromatographic analysis.
Gas chromatography was performed on a Hewlett-Packard
5890 series II gas chromatograph (Hewlett-Packard, Wald-
bronn, Germany) equipped with a BPX70 column (SGE, Wei-
terstadt, Germany) with 60 m length and 0.32 mm inner diame-
ter (19). The 13C-enrichment of individual fatty acid methyl
esters was measured by gas chromatography-combustion-isotope
ratio mass spectrometry (Hewlett-Packard GC interfaced to
Finnigan MAT delta S mass spectrometer, Bremen, Germany)
(19).
Expression of the results
From the 13C/12C ratio of the samples measured by gas chro-
matography-combustion-isotope ratio mass spectrometry, the
13C relative to the international PDB (Pee Dee Belemnite) stan-
dard and the 13C atom percentage excess (APE) were calculated
(20), representing the fatty acid enrichment evaluated. The con-
centrations of the labeled fatty acids (mol/l or mol/g) were
calculated by multiplying the absolute concentrations of the fatty
acids by their APE values.
As an estimation of the mean enrichment of tracer in the
maternal plasma during all the experiment, we calculated the
area under the curve from the mol/l tracer of the individual
fatty acids in the maternal plasma according the trapezoidal
rule. The transfer ratio of the labeled fatty acids from the
mother to the fetus was estimated by the percentage of tracer
concentration (mol 13C/l) in cord blood relative to the area
under the tracer concentration curve in the maternal plasma
(Table 4).
The distribution of [13C]tracer between placental tissue and




The results are expressed as mean  SEM. Statistically sig-
nificant differences were assessed using a Student’s t-test. The
significance level was set a P 	 0.05. All analyses were per-






fatty acid amount in placenta nmol g⁄( ) APE C13[ ]placenta⋅




The absolute concentration (mg/l) of the fatty acids stud-
ied at delivery was significantly higher (P 	 0.05) in maternal
plasma PL (PA: 490  54, OA: 152  17; LA: 281  42; DHA:
72  14) than in cord plasma PL (PA: 160  36; OA: 39  7;
LA: 40 11; DHA: 33  9). Table 1 shows the percentage
values of these selected fatty acids, as well as some fatty
acid indices, in the lipid fractions of maternal plasma,
cord plasma and placental tissue. Only total LC-PUFA pro-
portions were higher in every lipid fraction in cord
plasma, than in maternal plasma; in TG fraction, the DHA
percentage was higher in cord plasma than in maternal
plasma (Table 1). For the placental tissue, high DHA pro-
portions were found in PL, TG, and NEFA, but not in the
CE fraction. PL were the most abundant lipid fraction in
the placenta (Table 1).
Fig. 1. Enrichment [[13C]atom percent excess (APE) %] of fatty
acids in maternal plasma during the time of study (diamond,
docosahexaenoic acid (DHA); triangle, linoleic acid (LA); circle,
oleic acid (OA); square, palmitic acid C16:0 (PA)]. Results are ex-
pressed as mean  SEM.
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Figure 1 shows the evolution of 13C-enrichment of the
labeled fatty acids in maternal plasma during the experi-
mental time. The enrichment of the [13C]fatty acids in
maternal plasma was maximal at the time of delivery in
NEFA and TG. One hour after delivery (time 1), the
13C-enrichments of the fatty acids continued in a similar
range, showing that at delivery a relative stable steady
state of tracer enrichment in these fractions was
achieved. The high enrichment in the [13C]DHA ob-
served in these fractions, relative to the other fatty acids,
was only due to the higher dose intake of the DHA tracer
relative to the DHA concentration in plasma. 13C-enrich-
ments were hardly detected in maternal PL, and no in-
corporation into the CE fraction was detected during the
time of this study.
The enrichment of the [13C]fatty acids in TG and
NEFA fractions of maternal plasma, placenta, and cord
plasma at the time of delivery is shown in Fig. 2. We de-
tected a different distribution of the 13C-enrichment be-
tween placenta and cord plasma lipids. 13C-enrichments
tended to be higher in maternal plasma TG than in pla-
centa TG or in cord plasma TG, reflecting a materno-
fetal flux. In contrast, the enrichments of the labeled
fatty acids in the NEFA fraction were higher in cord plasma
than in placenta (maternal NEFA cord plasma NEFA
placenta NEFA), although the differences were only sta-
tistically significant for the nonesterified OA and DHA.
In cord plasma, the APE values in NEFA were signifi-
cantly higher than in the TG fraction for [13C]DHA and
[13C]OA. In placenta, [13C]PA was significantly more in-
corporated into TG than into NEFA. A similar trend was
also observed for the other fatty acids, but did not reach
statistical significance (Fig. 2).
Table 2 shows the concentrations of tracer in the differ-
ent lipid fractions of plasma and placenta at the time of
delivery. In the placenta, most of the tracer fatty acids
were esterified into placenta PL.
In order to estimate the distribution of the labeled fatty
acids within the different lipid fractions of cord plasma, we
calculated the percentage of the mol/l of tracer in all
lipid fractions (Table 3). The results indicate that [13C]PA,
[13C]OA, and [13C]LA are mainly found in NEFA and TG
of cord plasma, while [13C]DHA was distributed in similar
proportions among all fractions, although the differences
were not statistically significant. This different distribution
of DHA, as compared with the other fatty acids, might re-
flect differences in the transfer mechanisms of DHA, and is
considered by some authors as an effect of compartmental-
ization of the lipids by the placenta (Table 3).
We calculated the percentage of mol/l tracer fatty ac-
ids in cord plasma relative to the area under the tracer
concentration curve in maternal plasma to estimate the
ratio of placental transfer of labeled fatty acids from
mother to fetus (Table 4). Due to a large variability in the
results, there were no statistically significant differences.
No preferential transfer of any of the fatty acids studied
was evident (Table 4); however, the ratio of the fatty acid
concentration in placental tissue to that in maternal
plasma is significantly higher for [13C]DHA than for the
other fatty acids (Fig. 3). Furthermore, the placenta/
plasma ratio for [13C]LA was significantly higher than that
for [13C]OA (Fig. 3).
Fig. 2. APE values of tracer fatty acids in triglycerides and nonesterified fatty acids (NEFA) in maternal plasma, placenta and cord plasma
at the time of delivery [(black bar, triglycerides (TG); striped bar, NEFA]. Results are expressed as mean  SEM. a Statistically significant dif-
ferences (P 	 0.05) between nonesterified fatty acids enrichment of placenta and cord plasma. *Statistically significant differences (P 	
0.05) between nonesterified fatty acids and triglycerides.










Larqué et al. Human placental transfer of fatty acids 53
DISCUSSION
The materno-fetal transfer of fatty acids is considered to
depend in part on concentration gradients across the pla-
centa (21) that is enhanced by maternal gestational hyper-
lipidemia (3). This study confirms higher concentrations
of individual fatty acids in maternal than in cord plasma,
compatible with a gradient driven fatty acid flux from the
mother to the fetus. The observed percentages of DHA
and total LC-PUFA were within the range previously re-
ported by others authors (3, 4) and higher in cord than in
maternal plasma, which is in agreement with a preferen-
tial transfer of LC-PUFA to the neonatal circulation.
Four hours after tracer ingestion, there is some enrich-
ment of [13C]fatty acids in the maternal plasma TG and
NEFA, while little has been esterified into PL and CE at
this time (Fig. 1). However, since the placenta is reported
to utilize almost exclusively fatty acids from maternal
plasma TG and NEFA fractions for transfer to the fetus
(8), we consider that this experimental design allows satis-
factory evaluation of the transfer of the labeled fatty acids.
The 13C-enrichment of cord blood NEFA shows a trend
to be higher than the [13C]enrichment in placental NEFA
(Fig. 2) with statistically significant differences for NEFA
OA and DHA, which lead us to conclude that there are
different compartments of human placental NEFA. In
agreement with this hypothesis, Hummel et al.(22) re-
ported indications for the existence of two different pools
of free fatty acids in rat placenta. They studied the placen-
tal transfer of [14C]PA administrated intravenously at in-
tervals from 0.3 min to 300 min to pregnant rats. They de-
scribed one compartment, accounting for only 5% of the
total placental free fatty acids, which represented mater-
nal free fatty acids passing across the placenta. The sec-
ond compartment comprised 95% of the placental free
fatty acids and appeared not to take part in materno-fetal
fatty acid transport (22). If only a small part of placental
NEFA is involved in the transfer, this could explain the rel-
atively low enrichment of total NEFA in the placenta in
the present study, since the enrichment measured by us is
obtained from the mixture of both NEFA pools. Another
possibility that could explain the lower enrichment in pla-
cental NEFA than in cord plasma NEFA would be a meth-
odological error, since part of the placental PL might have
been hydrolyzed by phospholipase A2 of the placenta (23)
and have diluted the tracer in the NEFA fraction during
the time span between delivery and sample freezing. How-
ever, the placental samples we studied were obtained and fro-
zen in liquid nitrogen immediately after cesarean section,
thus we assume that lipolysis should be minimal (24).
The lipid fraction in which the fatty acids are present in
the placenta might influence their rate of transfer (Table
2). It is known that transient esterification is an intermedi-
ate step in the placental fatty acid transport of some of the
NEFA. Szabo et al. (25) estimated that about 20% of iso-
tope labeled palmitate was esterified in placental TG after
2 h of incubation of human placental tissue. Cultured hu-
man term trophoblast cells incubated with radiolabeled
oleate for 24 h released to the medium high proportions
of NEFA, while labeled PL and TG were retained in the
cells (26). Thus, NEFA bound to cytosolic fatty acid bind-
ing proteins (8) are transferred into cord plasma faster
TABLE 3. Distribution of [13C]labeled fatty acids within the lipid 
fractions of cord plasma
PA OA LA DHA
%
PL 24  8 13  6 15  7 37  13
TTG 30  5 29  7 33  7 26  7
NEFA 46  12 59  7 52  1 36  7
PL, phospholipids; TG, triglycerides; NEFA, nonesterified fatty ac-
ids. Results are expressed as mean  SEM. No significant differences.
TABLE 4. Estimation of tracer fatty acids transfer from the mother 
to the neonate
PA OA LA DHA
mol/l tracer cord plasma/AUC maternal plasma (%)
PL 1.63  1.45 0.36  0.43 0.38  0.34 1.17  0.63
TG 1.92  1.30 0.81  0.46 0.70  0.49 0.70  0.53
NEFA 3.03  2.54 1.97  1.48 1.13  0.90 1.14  0.89
Totala 6.59  4.94 3.14  2.08 2.22  1.83 3.01  1.59
Results are expressed as mean  SEM. No significant differences.
a Total, sum of labeled fatty acids transfer in phospholipids  tri-
glycerides  nonesterified fatty acids.
TABLE 2. Concentration of tracer in maternal plasma (mol 13C/l), placenta (nmol 13C/g) and cord plasma 
(mol 13C/l) in the lipid fractions at the time of delivery
Phospholipids PA OA LA DHA
Maternal plasma 0.18  0.11 0.23  0.12 1.39  0.42 0.23  0.05
Placenta 0.45  0.27 0.36  0.11 0.97  0.42 0.86  0.20
Cord plasma 0.16  0.06 0.06  0.03 0.03  0.01 0.04  0.01
Triglycerides
Maternal plasma 11.67  2.14 14.36  3.67 11.42  2.17 3.58  0.66
Placenta 0.29  0.06 0.23  0.09 0.18  0.07 0.16  0.07
Cord plasma 0.20  0.03 0.12  0.02 0.09  0.02 0.03  0.01
NEFA
Maternal plasma 2.22  0.39 2.35  0.49 1.57  0.21 0.43  0.13
Placenta 0.05  0.05 0.12  0.05 0.25  0.07 0.16  0.04
Cord plasma 0.33  0.10 0.27  0.07 0.15  0.04 0.04  0.01
Results are expressed as mean  SEM.
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than PL, CE, or TG. The synthesis of apolipoprotein B in
rat placenta (27), and the identification of small amounts
of lipoproteins very similar to LDL and VLDL in human
term placentas (with most of the cellular PL and TG
present in the preparation) (28), suggests a probable
mechanism of exportation of the esterified fatty acids to
the fetal side, which takes longer time than the transfer of
NEFA.
Kuhn and Crawford (10) reported that perfused hu-
man placenta transferred [14C]AA mostly into fetal
phosphoglycerides, which do not recross the placental
barrier and thus may be retained in the fetal circulation,
while [14C]LA was found mostly in NEFA, which may
cross the placenta in either direction. A different com-
partmentalization of individual fatty acids by the pla-
centa might be a powerful mechanism for selective
transfer of fatty acids. In the present study, [13C]DHA
was esterified in similar proportions into PL, TG, and
NEFA of cord lipids (Table 3), while the other tracers
were mainly incorporated into NEFA and TG, although
the differences were not statistically significant. The rel-
ative esterification of [13C]DHA in cord PL in this study
(37%) was lower than that reported for [14C]AA by
Kuhn and Crawford (59.4%) (10). Differences in the
distribution between DHA and AA were also described
in BeWo cells where almost 37% of [14C]DHA was ester-
ified into PL relative to the 60% for [14C]AA (29). The
role of AA as precursor of eicosanoids might influence
its selective accumulation in placental membrane PL
and might explain differences to the placental transfer
of DHA.
The concept of a preferential and selective transfer of
LC-PUFA emerged from observations that maternal
plasma lipids at birth contained higher percentage lev-
els of the precursors ALA and LA than cord blood lipids
of their infants, but percentage values for LC-PUFA
were clearly and significantly higher in infants than in
their mothers (3, 4). In contrast, some studies per-
formed in human perfused placentas showed a higher
rate of placental transfer for LA that for AA (10, 13).
Haggarty et al. (30) recently reported that the fatty acid
composition of the perfusate markedly modifies placen-
tal fatty acid transfer. While the selectivity for individual
PUFA was DHAALALAAA when the placenta was
perfused with fatty acids in the same ratios as found in
circulating TG of pregnant women in the last trimester
of pregnancy, the preference changed to DHA
AAALALA when the maternal perfusate contained
fatty acids in the same ratios as found in circulating
NEFA.
In the present in vivo study, the tracer free fatty acids
were administrated orally 4 h before delivery, and no
preferential transfer of individual fatty acids across the
placenta was detected (Table 4). However, we demon-
strate a preferential sequestration of DHA into the hu-
man placenta relative to essential fatty acids and NEFA
(Fig. 3). This result is in agreement with the preferential
binding of maternal DHA by the FABPpm of the pla-
centa described by other authors (8, 9). The DHA up-
take in placental tissue might play an important role for
the DHA transfer. Haggarty et al. (13) did not detect any
preferential accumulation of [14C]DHA in the perfused
human placenta, but they found a preferential materno-
fetal transfer of DHA. It appears possible that DHA
transfer is a slow stepwise process, with initial placental
uptake of DHA and later release into the fetal circula-
tion. Our experiment may have detected mostly the first
part of this process occurring until 4 h after tracer ad-
ministration. Since we could not detected enrichment
of tracer in PL and CE in the maternal side, it is unlikely
that the time was sufficient to investigate the transfer of
labeled fatty acids involving these components. Further
studies with longer time intervals between tracer admin-
istration and delivery might contribute to describing the
transfer process. It is likely that the results obtained 8 h,
12 h, or 24 h after administration of the labeled isotopes
would be considerably different, but longer time frame
studies also imply dilution of tracer by dietary intake and
the fatty acids transferred quickly to the fetus as NEFA
might already have been incorporated into fetal tissues.
In conclusion, the results of the present study demon-
strate that stable isotope labeled fatty acids adminis-
trated 4 h before delivery to pregnant women appear in
maternal TG and NEFA, but hardly in PL. The 13C-
enrichment of cord blood NEFA tended to be higher
than the 13C-enrichment in placental NEFA, which we
interpret to reflect the existence of different pools of
placental NEFA. Placental tissue shows a preferential in-
corporation of DHA relative to LA, OA, and PA at the
studied time point, which may reflect a metabolic mech-
anism for a preferential materno-fetal DHA transfer.
E.L. was the recipient of a fellowship provided by the Hum-
boldt Foundation (Germany). This work was partially sup-
ported by the German Research Council-Deutsche For-
schungsgemeinschaft (Ko 912/5-1 and 5-2). Furthermore,
the studies reported herein have been carried out partially
with financial support from the Commission of the European
Fig. 3. Ratio between placental and maternal plasma concentra-
tion of [13C]fatty acids at the time of delivery. Results are expressed
as mean  SEM. Means with no letters in common are significantly
different, P 	 0.05.
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Dietary Fatty Acids on the Pathophysiology of Intrauterine
Foetal Growth and Neonatal Development” (PeriLip). This
paper does not necessarily reflect its views and in no way an-
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